Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease

D. Mekahli, MC. Liebau, MA. Cadnapaphornchai, SL. Goldstein, LA. Greenbaum, M. Litwin, T. Seeman, F. Schaefer, LM. Guay-Woodford

. 2023 ; 24 (1) : 33. [pub] 20230213

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu multicentrická studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004188

PURPOSE: Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoing clinical trials (Study 204, Study 307) to evaluate safety, tolerability, and efficacy of tolvaptan in children with ARPKD. METHODS: Both trials are of multinational, multicenter, open-label design. Age range at enrollment is 28 days to < 12 weeks in Study 204 and 28 days to < 18 years in Study 307. Subjects in both studies must have a clinical diagnosis of ARPKD, and those in Study 204 must additionally have signs indicative of risk of rapid progression to KRT, namely, all of: nephromegaly, multiple kidney cysts or increased kidney echogenicity suggesting microcysts, and oligohydramnios or anhydramnios. Target enrollment is 20 subjects for Study 204 and ≥ 10 subjects for Study 307. RESULTS: Follow-up is 24 months in Study 204 (with optional additional treatment up to 36 months) and 18 months in Study 307. Outcomes include safety, tolerability, change in kidney function, and percentage of subjects requiring KRT relative to historical data. Regular safety assessments monitor for possible adverse effects of treatment on parameters such as liver function, kidney function, fluid balance, electrolyte levels, and growth trajectory, with increased frequency of monitoring following tolvaptan initiation or dose escalation. CONCLUSIONS: These trials will provide data on tolvaptan safety and efficacy in a population without disease-specific treatment options. TRIAL REGISTRATION: Study 204: EudraCT 2020-005991-36; Study 307: EudraCT 2020-005992-10.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004188
003      
CZ-PrNML
005      
20230425141208.0
007      
ta
008      
230418s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12882-023-03072-x $2 doi
035    __
$a (PubMed)36782137
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mekahli, Djalila $u PKD Research Group, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium. djalila.mekahli@uzleuven.be $u Department of Pediatric Nephrology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. djalila.mekahli@uzleuven.be
245    10
$a Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease / $c D. Mekahli, MC. Liebau, MA. Cadnapaphornchai, SL. Goldstein, LA. Greenbaum, M. Litwin, T. Seeman, F. Schaefer, LM. Guay-Woodford
520    9_
$a PURPOSE: Autosomal recessive polycystic kidney disease (ARPKD) is a hereditary condition characterized by massive kidney enlargement and developmental liver defects. Potential consequences during childhood include the need for kidney replacement therapy (KRT). We report the design of 2 ongoing clinical trials (Study 204, Study 307) to evaluate safety, tolerability, and efficacy of tolvaptan in children with ARPKD. METHODS: Both trials are of multinational, multicenter, open-label design. Age range at enrollment is 28 days to < 12 weeks in Study 204 and 28 days to < 18 years in Study 307. Subjects in both studies must have a clinical diagnosis of ARPKD, and those in Study 204 must additionally have signs indicative of risk of rapid progression to KRT, namely, all of: nephromegaly, multiple kidney cysts or increased kidney echogenicity suggesting microcysts, and oligohydramnios or anhydramnios. Target enrollment is 20 subjects for Study 204 and ≥ 10 subjects for Study 307. RESULTS: Follow-up is 24 months in Study 204 (with optional additional treatment up to 36 months) and 18 months in Study 307. Outcomes include safety, tolerability, change in kidney function, and percentage of subjects requiring KRT relative to historical data. Regular safety assessments monitor for possible adverse effects of treatment on parameters such as liver function, kidney function, fluid balance, electrolyte levels, and growth trajectory, with increased frequency of monitoring following tolvaptan initiation or dose escalation. CONCLUSIONS: These trials will provide data on tolvaptan safety and efficacy in a population without disease-specific treatment options. TRIAL REGISTRATION: Study 204: EudraCT 2020-005991-36; Study 307: EudraCT 2020-005992-10.
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a novorozenec $7 D007231
650    _2
$a tolvaptan $x terapeutické užití $7 D000077602
650    12
$a polycystické ledviny autozomálně recesivní $x diagnostické zobrazování $x farmakoterapie $7 D017044
650    12
$a polycystické ledviny autozomálně dominantní $7 D016891
650    _2
$a ledviny $7 D007668
650    _2
$a longitudinální studie $7 D008137
650    12
$a cysty $x farmakoterapie $7 D003560
650    _2
$a antagonisté antidiuretického hormonu $x škodlivé účinky $7 D065092
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Liebau, Max C $u Department of Pediatrics, Center for Family Health, Center for Rare Diseases, and Center for Molecular Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany $1 https://orcid.org/0000000304949080
700    1_
$a Cadnapaphornchai, Melissa A $u Rocky Mountain Pediatric Kidney Center, Rocky Mountain Hospital for Children at Presbyterian/St. Luke's Medical Center, Denver, CO, USA $1 https://orcid.org/0000000204602477
700    1_
$a Goldstein, Stuart L $u Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA $1 https://orcid.org/0000000337118785
700    1_
$a Greenbaum, Larry A $u Department of Pediatrics, Division of Pediatric Nephrology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, USA $1 https://orcid.org/000000022490021X
700    1_
$a Litwin, Mieczyslaw $u Department of Nephrology, Kidney Transplantation and Arterial Hypertension, Children's Memorial Health Institute, Warsaw, Poland $1 https://orcid.org/0000000252412483
700    1_
$a Seeman, Tomas $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Schaefer, Franz $u Division of Pediatric Nephrology, University Children's Hospital Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000175649937
700    1_
$a Guay-Woodford, Lisa M $u Center for Translational Research, Children's National Research Institute, Washington, DC, USA $1 https://orcid.org/0000000261873927
773    0_
$w MED00008194 $t BMC nephrology $x 1471-2369 $g Roč. 24, č. 1 (2023), s. 33
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36782137 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141204 $b ABA008
999    __
$a ok $b bmc $g 1924699 $s 1190397
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 1 $d 33 $e 20230213 $i 1471-2369 $m BMC nephrology $n BMC Nephrol $x MED00008194
LZP    __
$a Pubmed-20230418
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace